BioCryst Rises on Midstage Study Results
NEW YORK (AP) — Shares of BioCryst Pharmaceuticals climbed Tuesday after the company reported successful clinical trial results for a drug designed to treat a rare condition called hereditary angioedema.
Hereditary angioedema, or HAE, causes unpredictable and potentially deadly swelling attacks that affect the larynx, abdomen and face. BioCryst's drug is intended to prevent those attacks. The company said patients who took its drug BCX4161 were less likely to have an HAE attack over the 28-day study.
More testing will to be done to demonstrate that the drug works and is safe before it can win federal approval.
BioCryst Pharmaceuticals Inc. stock gained 90 cents, or 9.9 percent, to $9.90 in afternoon trading. Shares of the Research Triangle Park, North Carolina, company rose as much as 21.9 percent earlier in the day.